[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-drug":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100563776","phase-4-improving-efficacity-of-sleeve-gastrectomy-with-naltrexonebupropion-extended-release-tablet-100563776",false,"NCT06620562","Improving Efficacity of Sleeve Gastrectomy With Naltrexone\u002FBupropion Extended-release Tablet","Improving Efficacity of Sleeve Gastrectomy With Naltrexone\u002FBupropion Extended-release Tablet - A Randomized Controlled Trial","Inclusion Criteria:\n\n* MBI above 30 kg\u002Fm2 with obesity-related comorbidity or above 35 kg\u002Fm2 without associated comorbidities.\n\nExclusion Criteria:\n\n* Revisional or reoperative surgery\n* Pregnancy or planned pregnancy in the next 24 months\n* Simultaneous use of other weight loss medication\n* Uncontrolled hypertension\n* Chronic opioid use or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal.\n* Use of other bupropion-containing products\n* Concomitant administration of monoamine oxidase inhibitors.\n* End-stage liver or kidney disease\n* Concomitant use of CYP2B6 inhibitors (ticlopidine or clopidogrel)\n* Concomitant administration of the antipsychotic thioridazine\n* Seizure disorder or a history of seizures\n* Cardiac pacemaker\n* Current or prior diagnosis of bulimia or anorexia nervosa","ALL","18 Years","65 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.\n\nResearchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.\n\nParticipants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone\u002FBupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.",[27,28],"Obesity; Drug","Obesity, Morbid","RECRUITING","2025-08-04",{"date":32,"type":33},"2025-08-08","ACTUAL",{"date":35,"type":33},"2025-06-04",{"date":37,"type":21},"2028-08",{"name":39,"class":40},"Laval University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":5},"100549230","nutritional-therapy-to-incretin-based-anti-obesity-medications-in-the-management-of-gastrointestinal-adverse-events-100549230","NCT06431308","Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events","Adjuvant Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events During the Up-titration Phase","Inclusion Criteria:\n\n* individuals aged ≥ 18 years\n* eligible to receive AOM \\[i.e., BMI ≥ 30 kg\u002Fm2 or ≥ 27 kg\u002Fm2 with at least one adiposity-related coexisting condition (e.g., diabetes or pre-diabetes, hypertension, dyslipidemia, obstructive sleep apnea, fatty liver, cardiovascular disease)\\]\n* who can read and speak Hebrew.\n\nExclusion Criteria:\n\n* Contraindications or precautious for treatment with Wegovy© or Mounjaro© \\[i.e., personal or family history of medullary thyroid cancer (MTC), personal history of multiple endocrine neoplasia type 2 (MEN2) syndrome, attempting conception, current pregnancy or breastfeeding\\]\n* previous bariatric surgery or endo-bariatric procedure\n* presence of chronic pancreatitis\n* treatment with AOM within a month before enrollment\n* patients with type 1 diabetes mellitus\n* patients who underwent other major GI surgery prior to medication treatment\n* patient with underlying GI disease \\[e.g., gastroparesis, celiac, Inflammatory Bowel Disease (IBD)\\]\n* a positive diagnosis of small-intestinal bacterial overgrowth (SIBO)\n* patients with active gastritis, gastroenteritis\n* chronic usage of promotility drugs or laxatives\n* patients with uncontrolled mental illness\n* significant cognitive deterioration\n* alcohol consumption exceeding 1 drink per day for women and 2 drinks per day for men .\n\nIn addition, participants who decide not to initiate or stop Wegovy© or Mounjaro© treatment for more than two consecutive injections for any reason or who undergo bariatric surgery or endoscopic sleeve gastroplasty during the study period will be excluded from the study",true,{"count":51,"type":21},120,[53],"NA","The goal of the study is to evaluate the effect of nutrition intervention on gastrointestinal symptoms, treatment discontinuation rate, nutritional parameters (e.g., dietary intake and eating habits), anthropometric measures, functional parameters, and QOL during the initiation and up-titration phase of incretin-based Anti Obesity Medications (AOM) treatment in patients with overweight\u002Fobesity.\n\nThe nutrition intervention protocol will be developed based on literature review, focus groups with health care professionals, and patient interviews.\n\nA single-center pilot study will be performed at the Tel-Aviv Assuta Medical Center, among 10 patients who are about to initiate long-term weight management treatment with Wegovy© (semaglutide 2.4 mg), followed by a multi-center, parallel design open-label, RCT, which will be conducted at the Tel-Aviv Assuta Medical Center and Rabin Medical Center - Beilinson Hospital, in 120 patients who are about to initiate long-term weight management treatment with Wegovy© or Mounjaro© .\n\nThe intervention group will receive nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s). The control group will receive the usual nutrition care for patients treated with AOM.\n\nPrimary outcomes (gastrointestinal symptom assessment) and secondary outcomes (incretin-based AOM discontinuation rate, nutritional parameters, anthropometrics, functional parameters and QOL) will be evaluated by interviews, questionnaires and measurements at baseline, at the end of Wegovy© or Mounjaro© titration phase \\[20 weeks (T1)\\] and weekly during the study period (for GI symptoms assessment).",[27],"2025-04-21",{"date":58,"type":33},"2025-04-24",{"date":60,"type":33},"2025-01-30",{"date":62,"type":21},"2026-03-30",{"name":64,"class":40},"Ariel University",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100581947","impact-of-antiobesity-medications-on-appetite-and-appetite-related-hormones-and-metabolites-100581947","NCT06856928","Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.","Inclusion Criteria:\n\n* Adult males and females with a BMI of 30-45 kg\u002Fm2 (early group), or a BMI of 30-45 kg\u002Fm2 prior to weight loss achieved through medication (late group)\n* Age, 25-60 years old\n* Passing medical and physical screening, and analysis of blood and urine screening samples\n* Anticipated to start or are already prescribed AOMs (semaglutide or tirzepatide)\n* 6-months weight stable (early group) or 3 months weight stable at current weight (late group)\n* Women of reproductive age must be using an effective form of contraception\n\nExclusion Criteria:\n\n* Diagnosed with type 1 or 2 diabetes\n* Smoker\n* Previous surgical treatment or device-based therapy for obesity\n* Chronic or acute pancreatitis\n* Clinically significant gastric emptying abnormality\n* Uncontrolled hypertension or hypo\u002Fhyperthyroidism\n* Cardiovascular event 3 months within screening\n* Acute or chronic hepatitis\n* Inability to tolerate beef, eggs, and cheese\n* Women who are pregnant\n* Women who are nursing","25 Years","60 Years",{"count":74,"type":21},16,"OBSERVATIONAL","This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.",[27],[79,80,81],"appetite-related hormones","appetite","metabolites","NOT_YET_RECRUITING","2025-02-26",{"date":85,"type":33},"2025-03-04",{"date":87,"type":21},"2025-03",{"date":89,"type":21},"2027-12",{"name":91,"class":40},"University of Colorado, Denver"]